<p>Merus N.V.（納斯達克代碼：MRUS - 獲取免費報告）主要股東 A/S Genmab 於 12 月 18 日（星期四）交易中收購了 212,177 股 Merus 股票。這些股票的平均收購價格為每股 97.00 美元，總價值為 20,581,169.00 美元。交易後，該內部人士在公司持有 71,946,801 股，估計價值約為 6,978,839,697 美元。這代表其持股比例增加了 0.30%。此次收購已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。持有公司 10% 或以上股份的主要股東需向 SEC 披露其買賣情況。</p>
<p>A/S Genmab 最近還進行了以下交易：</p>
<ul>
<li>在 12 月 19 日（星期五），A/S Genmab 購買了 66,264 股 Merus 股票。這些股票的平均收購價格為每股 97.00 美元，總交易額為 6,427,608.00 美元。</li>
<li>在 12 月 17 日（星期三），A/S Genmab 購買了 150,795 股 Merus 股票。這些股票的平均成本為每股 97.00 美元，總價值為 14,627,115.00 美元。</li>
<li>在 12 月 16 日（星期二），A/S Genmab 購買了 120,752 股 Merus 股票。這些股票的平均收購價格為每股 97.00 美元，總價值為 11,712,944.00 美元。</li>
</ul>
<h2>Merus 股票下跌 0.1%</h2>
<p>在週一的午盤交易中，Merus 股票下跌 0.06 美元，報 96.95 美元。該公司的股票交易量為 501,154 股，而其平均交易量為 1,271,123 股。該股票的市值為 73.5 億美元，市盈率為-18.29，貝塔值為 1.06。Merus N.V.的十二個月最低價為 33.19 美元，最高價為 97.14 美元。該股票的 50 日移動平均價格為 95.66 美元，200 日移動平均價格為 76.05 美元。</p>
<h2>分析師設定新目標價</h2>
<p>多家券商對 MRUS 進行了評估。Lifesci Capital 在 9 月 30 日（星期二）的研究報告中重申了對 Merus 的 “市場表現” 評級，並設定了 97.00 美元的目標價。巴克萊在 9 月 30 日（星期二）的研究報告中重申了 “持平” 評級，並將 Merus 的目標價下調至 97.00 美元（之前為 112.00 美元）。Leerink Partners 在 10 月 5 日（星期日）的研究報告中將 Merus 的評級從 “強力買入” 下調至 “持有”。工業聯盟證券在 8 月 25 日（星期一）的一份研究報告中設定了 Merus 的目標價為 90.00 美元。最後，Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Merus 的 “賣出（d-）” 評級。三位分析師對該股票給予了買入評級，十四位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Merus 目前的平均評級為 “持有”，平均目標價為 93.56 美元。</p>
<p><strong>查看我們對 MRUS 的最新分析</strong></p>
<h2>Merus 的機構交易</h2>
<p>機構投資者最近買賣了該公司的股票。Avoro Capital Advisors LLC 在第三季度將其在 Merus 的持股增加了 12.3%。Avoro Capital Advisors LLC 目前持有 3,542,500 股生物技術公司的股票，價值 333,526,000 美元，此前在上個季度增持了 386,945 股。Paradigm Biocapital Advisors LP 在第一季度將其在 Merus 的持股增加了 99.4%。Paradigm Biocapital Advisors LP 目前持有 3,369,699 股生物技術公司的股票，價值 141,831,000 美元，此前在上個季度增持了 1,679,777 股。Holocene Advisors LP 在第二季度將其在 Merus 的持股增加了 18.8%。Holocene Advisors LP 目前持有 2,225,241 股生物技術公司的股票，價值 117,048,000 美元，此前在上個季度增持了 351,616 股。Westfield Capital Management Co. LP 在第三季度將其在 Merus 的持股增加了 4.4%。Westfield Capital Management Co. LP 目前持有 2,132,489 股生物技術公司的股票，價值 200,774,000 美元，此前在上個季度增持了 90,101 股。最後，Woodline Partners LP 在第三季度將其在 Merus 的持股增加了 8.5%。Woodline Partners LP 目前持有 1,674,167 股生物技術公司的股票，價值 157,623,000 美元，此前在此期間增持了 131,267 股。機構投資者持有該公司 96.14% 的股份。</p>
<h2>關於 Merus</h2>
<p>（獲取免費報告）</p>
<p>Merus NV 是一家臨牀階段的免疫腫瘤學公司，專注於雙特異性抗體治療藥物的發現和開發，以治療癌症。利用其專有的 Biclonics®平台，Merus 設計了能夠同時與免疫細胞和腫瘤靶點結合的全人源雙特異性抗體。該公司的研究工作旨在創造具有優化效力、選擇性和安全性特徵的新療法。</p>
<p>Merus 的研發管線涵蓋多個處於臨牀前和臨牀開發不同階段的 Biclonics 候選藥物。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Merus 更好</li>
<li>華爾街股票挑選者評選 2026 年第一股票</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>Nvidia 首席執行官發出大膽的特斯拉呼籲</li>
<li>黃金警報</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9TVJVUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9TVJVUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Merus 嗎？</h2>
<p>在你考慮 Merus 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Merus 並不在名單上。</p>
<p>雖然 Merus 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MRUS

GMAB

<p>A/S Genmab 以每股 97 美元的價格收購了 212,177 股 Merus N.V.的股票，總計 2058 萬美元，增持幅度為 0.30%。該交易已向 SEC 披露。Merus 的股票目前交易價格為 96.95 美元，市值為 73.5 億美元。分析師對 Merus 的評級不一，平均目標價為 93.56 美元。機構投資者積極交易 Merus 股票，Avoro Capital Advisors LLC 等公司的持股顯著增加</p>

<p>Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab acquired 212,177 shares of Merus stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $97.00 per share, with a total value of $20,581,169.00. Following the transaction, the insider owned 71,946,801 shares in the company, valued at approximately $6,978,839,697. This represents a 0.30% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.</p>
<div class="lb-trans"><p>Merus N.V.（納斯達克代碼：MRUS - 獲取免費報告）主要股東 A/S Genmab 於 12 月 18 日（星期四）交易中收購了 212,177 股 Merus 股票。這些股票的平均收購價格為每股 97.00 美元，總價值為 20,581,169.00 美元。交易後，該內部人士在公司持有 71,946,801 股，估計價值約為 6,978,839,697 美元。這代表其持股比例增加了 0.30%。此次收購已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。持有公司 10% 或以上股份的主要股東需向 SEC 披露其買賣情況。</p>
</div><p>A/S Genmab also recently made the following trade(s):</p>
<div class="lb-trans"><p>A/S Genmab 最近還進行了以下交易：</p>
</div><ul>
<li>On Friday, December 19th, A/S Genmab bought 66,264 shares of Merus stock. The stock was acquired at an average price of $97.00 per share, for a total transaction of $6,427,608.00.</li>
<li>On Wednesday, December 17th, A/S Genmab bought 150,795 shares of Merus stock. The shares were acquired at an average cost of $97.00 per share, with a total value of $14,627,115.00.</li>
<li>On Tuesday, December 16th, A/S Genmab bought 120,752 shares of Merus stock. The shares were acquired at an average price of $97.00 per share, with a total value of $11,712,944.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 19 日（星期五），A/S Genmab 購買了 66,264 股 Merus 股票。這些股票的平均收購價格為每股 97.00 美元，總交易額為 6,427,608.00 美元。</li>
<li>在 12 月 17 日（星期三），A/S Genmab 購買了 150,795 股 Merus 股票。這些股票的平均成本為每股 97.00 美元，總價值為 14,627,115.00 美元。</li>
<li>在 12 月 16 日（星期二），A/S Genmab 購買了 120,752 股 Merus 股票。這些股票的平均收購價格為每股 97.00 美元，總價值為 11,712,944.00 美元。</li>
</ul>
</div><h2>Merus Stock Down 0.1%</h2>
<div class="lb-trans"><h2>Merus 股票下跌 0.1%</h2>
</div><p>Merus stock traded down $0.06 during mid-day trading on Monday, hitting $96.95. The company's stock had a trading volume of 501,154 shares, compared to its average volume of 1,271,123. The stock has a market capitalization of $7.35 billion, a P/E ratio of -18.29 and a beta of 1.06. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $97.14. The stock's fifty day moving average price is $95.66 and its two-hundred day moving average price is $76.05.</p>
<div class="lb-trans"><p>在週一的午盤交易中，Merus 股票下跌 0.06 美元，報 96.95 美元。該公司的股票交易量為 501,154 股，而其平均交易量為 1,271,123 股。該股票的市值為 73.5 億美元，市盈率為-18.29，貝塔值為 1.06。Merus N.V.的十二個月最低價為 33.19 美元，最高價為 97.14 美元。該股票的 50 日移動平均價格為 95.66 美元，200 日移動平均價格為 76.05 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of brokerages have weighed in on MRUS. Lifesci Capital reaffirmed a &#34;market perform&#34; rating and issued a $97.00 price target on shares of Merus in a research report on Tuesday, September 30th. Barclays reiterated an &#34;equal weight&#34; rating and issued a $97.00 price objective (down previously from $112.00) on shares of Merus in a research report on Tuesday, September 30th. Leerink Partnrs downgraded shares of Merus from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, October 5th. Industrial Alliance Securities set a $90.00 target price on shares of Merus in a research note on Monday, August 25th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Merus in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Merus currently has an average rating of &#34;Hold&#34; and an average price target of $93.56.</p>
<div class="lb-trans"><p>多家券商對 MRUS 進行了評估。Lifesci Capital 在 9 月 30 日（星期二）的研究報告中重申了對 Merus 的 “市場表現” 評級，並設定了 97.00 美元的目標價。巴克萊在 9 月 30 日（星期二）的研究報告中重申了 “持平” 評級，並將 Merus 的目標價下調至 97.00 美元（之前為 112.00 美元）。Leerink Partners 在 10 月 5 日（星期日）的研究報告中將 Merus 的評級從 “強力買入” 下調至 “持有”。工業聯盟證券在 8 月 25 日（星期一）的一份研究報告中設定了 Merus 的目標價為 90.00 美元。最後，Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Merus 的 “賣出（d-）” 評級。三位分析師對該股票給予了買入評級，十四位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Merus 目前的平均評級為 “持有”，平均目標價為 93.56 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on MRUS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 MRUS 的最新分析</strong></p>
</div><h2>Institutional Trading of Merus</h2>
<div class="lb-trans"><h2>Merus 的機構交易</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC grew its position in Merus by 12.3% during the 3rd quarter. Avoro Capital Advisors LLC now owns 3,542,500 shares of the biotechnology company's stock worth $333,526,000 after acquiring an additional 386,945 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after acquiring an additional 1,679,777 shares in the last quarter. Holocene Advisors LP lifted its stake in shares of Merus by 18.8% in the second quarter. Holocene Advisors LP now owns 2,225,241 shares of the biotechnology company's stock valued at $117,048,000 after buying an additional 351,616 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Merus by 4.4% in the third quarter. Westfield Capital Management Co. LP now owns 2,132,489 shares of the biotechnology company's stock valued at $200,774,000 after purchasing an additional 90,101 shares during the last quarter. Finally, Woodline Partners LP grew its stake in Merus by 8.5% in the 3rd quarter. Woodline Partners LP now owns 1,674,167 shares of the biotechnology company's stock valued at $157,623,000 after purchasing an additional 131,267 shares during the period. Institutional investors own 96.14% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近買賣了該公司的股票。Avoro Capital Advisors LLC 在第三季度將其在 Merus 的持股增加了 12.3%。Avoro Capital Advisors LLC 目前持有 3,542,500 股生物技術公司的股票，價值 333,526,000 美元，此前在上個季度增持了 386,945 股。Paradigm Biocapital Advisors LP 在第一季度將其在 Merus 的持股增加了 99.4%。Paradigm Biocapital Advisors LP 目前持有 3,369,699 股生物技術公司的股票，價值 141,831,000 美元，此前在上個季度增持了 1,679,777 股。Holocene Advisors LP 在第二季度將其在 Merus 的持股增加了 18.8%。Holocene Advisors LP 目前持有 2,225,241 股生物技術公司的股票，價值 117,048,000 美元，此前在上個季度增持了 351,616 股。Westfield Capital Management Co. LP 在第三季度將其在 Merus 的持股增加了 4.4%。Westfield Capital Management Co. LP 目前持有 2,132,489 股生物技術公司的股票，價值 200,774,000 美元，此前在上個季度增持了 90,101 股。最後，Woodline Partners LP 在第三季度將其在 Merus 的持股增加了 8.5%。Woodline Partners LP 目前持有 1,674,167 股生物技術公司的股票，價值 157,623,000 美元，此前在此期間增持了 131,267 股。機構投資者持有該公司 96.14% 的股份。</p>
</div><h2>About Merus</h2>
<div class="lb-trans"><h2>關於 Merus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company's research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.</p>
<div class="lb-trans"><p>Merus NV 是一家臨牀階段的免疫腫瘤學公司，專注於雙特異性抗體治療藥物的發現和開發，以治療癌症。利用其專有的 Biclonics®平台，Merus 設計了能夠同時與免疫細胞和腫瘤靶點結合的全人源雙特異性抗體。該公司的研究工作旨在創造具有優化效力、選擇性和安全性特徵的新療法。</p>
</div><p>The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Merus 的研發管線涵蓋多個處於臨牀前和臨牀開發不同階段的 Biclonics 候選藥物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Merus</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>GOLD ALERT</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Merus 更好</li>
<li>華爾街股票挑選者評選 2026 年第一股票</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>Nvidia 首席執行官發出大膽的特斯拉呼籲</li>
<li>黃金警報</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=MRUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merus Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Merus 嗎？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Merus 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Merus 並不在名單上。</p>
</div><p>While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Merus 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Genmab A/S 收購了 212,177 股 Merus（NASDAQ:MRUS）的股票